Showing 6,241 - 6,260 results of 46,952 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((wt decrease) OR (mean decrease)) ))', query time: 1.30s Refine Results
  1. 6241
  2. 6242

    Overview of pathway differences observed between FLT3-ITD and FLT3-WT AML samples across the two studies. by David B. Rosen (104278)

    Published 2010
    “…White coloring and non-bold lines indicate decreased pathway activity. Dotted line from FLT3L to p-Stat5 in FLT3-WT samples indicates connectivity in a subset of patients. …”
  3. 6243
  4. 6244

    [Ca<sup>2+</sup>] dynamics comparison between WT network and blocking an individual NFA-sensitive channel. by Jesús Espinal-Enríquez (622164)

    Published 2014
    “…J) <i>CaKC</i> on scenario 2 (activating <i>CaKC</i>), the decrease in peak, average and amplitude values. The central column (B, E, H and K) is the comparison between amplitude and mean of the dynamics between the WT curve and those with altered channels. …”
  5. 6245
  6. 6246
  7. 6247

    3D-Printed Diamond–Titanium Composite: A Hybrid Material for Implant Engineering by Kate Fox (1793524)

    Published 2019
    “…The addition of diamond to the biomaterial results in a 30% decrease in the water contact angle, making the scaffolds more hydrophilic and improving cellular adhesion and proliferation.…”
  8. 6248
  9. 6249
  10. 6250

    Procedure related data, LBNP, LBPP and hypoxia. by Marcus Thudium (6441863)

    Published 2023
    “…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
  11. 6251

    Individual biometric data of patients. by Marcus Thudium (6441863)

    Published 2023
    “…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
  12. 6252

    The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution. by Pia Steensland (362091)

    Published 2013
    “…<p>Ezlopitant (5 and 10 mg/kg) significantly decreased consumption of the non-caloric 0.2% saccharin solution compared to vehicle. …”
  13. 6253
  14. 6254
  15. 6255
  16. 6256

    The NK1-receptor antagonist ezlopitant significantly and selectively decreases voluntary intake of both sucrose and ethanol. by Pia Steensland (362091)

    Published 2013
    “…<p>Ezlopitant decreased consumption of 5% sucrose (<b>A</b>), whereas only the highest dose of ezlopitant (10 mg/kg) decreased consumption of 20% ethanol (<b>B</b>). …”
  17. 6257
  18. 6258
  19. 6259
  20. 6260